Physician profile
Gary Mueck
NPI 1609885979
$1,691.50
in general payments reported to CMS, 2019-2025
29 companies · $960 in 2025
The $960 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.55 · 2022: $101 · 2023: $262 · 2024: $345 · 2025: $960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,567.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $356.63 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $213.15 | 2025 | |
| Lilly USA, LLC | $130.45 | 2022-2025 | Zepbound, Mounjaro, Amyvid |
| Eisai INC. | $110.02 | 2025 | |
| Abbott Laboratories | $87.97 | 2021-2024 | Freestyle Libre 3 |
| Inspire Medical Systems, INC. | $72.90 | 2023-2025 | Inspire |
| Antares Pharma, INC. | $72.12 | 2023-2024 | Xyosted, Nocdurna, Tlando |
| Dexcom, INC. | $68.44 | 2024-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $58.55 | 2023-2024 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $53.76 | 2022-2024 | Qelbree, Xyosted, Tlando |
| Pfizer INC. | $50.93 | 2025 | |
| Medtronic, INC. | $40.60 | 2023 | Intellis Adaptivestim |
| Neurelis, INC. | $39.62 | 2025 | Valtoco |
| Astrazeneca Pharmaceuticals Lp | $36.93 | 2024 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $35.73 | 2025 | Arexvy, Shingrix |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acella Pharmaceuticals, LLC | $26.16 | 2025 | NP Thyroid 60 |
| Noven Therapeutics, LLC | $24.32 | 2024 | Xelstrym |
| Shield Therapeutics INC | $22.34 | 2023 | Accrufer |
| Axsome Therapeutics, INC. | $21.31 | 2025 | Auvelity |
| Phadia US INC. | $21.22 | 2025 | Immunocap |
| Xeris Pharmaceuticals, INC. | $20.66 | 2025 | Keveyis |
| Sanofi Pasteur INC. | $19.59 | 2025 | |
| Corium, LLC | $17.93 | 2023 | Azstarys |
| Halozyme INC | $16.44 | 2023 | |
| Idorsia Pharmaceuticals US INC | $16.15 | 2023 | Quviviq |
| Verity Pharmaceuticals INC. | $15.81 | 2024 | Tlando |
| Tolmar, INC. | $15.65 | 2025 | Jatenzo |
| Phathom Pharmaceuticals, INC. | $14.71 | 2025 | Voquezna |
| Amgen INC. | $11.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Mueck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.